Relay Therapeutics, Inc. Common Stock (RLAY) — Analysis Summary
Relay Therapeutics, Inc. Common Stock (RLAY) has a market cap of $4.18B with year-over-year revenue growth of +53.4%. Net margin stands at -1800.6%. The stock trades at a P/E ratio of -14.6.
Key Takeaways
- Revenue changed +53.4% year-over-year
- Net margin of -1800.6%
- P/E ratio of -14.6
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, RLAY posted revenue growth of +53.4% and trades at a P/E of -14.6.
Relay Therapeutics, Inc. Common Stock (RLAY)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -2999.4% — severe operating losses
Net margin at -2763.6% — losses exceed revenue (possible one-time charges)
Revenue fell 32.6% vs the prior period.
The latest filing shows negative free cash flow.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
192
Headquarters
CAMBRIDGE, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.